GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (FRA:49BA) » Definitions » Shiller PE Ratio

BeiGene (FRA:49BA) Shiller PE Ratio : (As of Apr. 30, 2024)


View and export this data going back to 2016. Start your Free Trial

What is BeiGene Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


BeiGene Shiller PE Ratio Historical Data

The historical data trend for BeiGene's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Shiller PE Ratio Chart

BeiGene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BeiGene Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BeiGene's Shiller PE Ratio

For the Biotechnology subindustry, BeiGene's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeiGene's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeiGene's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where BeiGene's Shiller PE Ratio falls into.



BeiGene Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

BeiGene's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, BeiGene's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-3.219/129.4194*129.4194
=-3.219

Current CPI (Dec. 2023) = 129.4194.

BeiGene Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 0.000 98.326 0.000
201406 0.000 100.560 0.000
201409 -0.141 100.428 -0.182
201412 -0.057 99.070 -0.074
201503 -0.176 99.621 -0.229
201506 -0.094 100.684 -0.121
201509 -0.232 100.392 -0.299
201512 -0.794 99.792 -1.030
201603 -0.817 100.470 -1.052
201606 -0.694 101.688 -0.883
201609 -0.927 101.861 -1.178
201612 -0.898 101.863 -1.141
201703 -1.215 102.862 -1.529
201706 -1.388 103.349 -1.738
201709 2.181 104.136 2.711
201712 -1.843 104.011 -2.293
201803 -1.687 105.290 -2.074
201806 -2.448 106.317 -2.980
201809 -2.117 106.507 -2.572
201812 -3.999 105.998 -4.883
201903 -2.531 107.251 -3.054
201906 -1.266 108.070 -1.516
201909 -4.604 108.329 -5.500
201912 -5.733 108.420 -6.843
202003 -4.257 108.902 -5.059
202006 -3.810 108.767 -4.533
202009 -4.085 109.815 -4.814
202012 -4.274 109.897 -5.033
202103 0.546 111.754 0.632
202106 -4.341 114.631 -4.901
202109 -4.014 115.734 -4.489
202112 -5.407 117.630 -5.949
202203 -3.895 121.301 -4.156
202206 -5.165 125.017 -5.347
202209 -5.383 125.227 -5.563
202212 -4.050 125.222 -4.186
202303 -3.157 127.348 -3.208
202306 -3.360 128.729 -3.378
202309 1.827 129.860 1.821
202312 -3.219 129.419 -3.219

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BeiGene  (FRA:49BA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


BeiGene Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of BeiGene's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BeiGene (FRA:49BA) Business Description

Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

BeiGene (FRA:49BA) Headlines

No Headlines